Investigation of Psychoactive Medications: Challenges and a Practical and Scalable New Path
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2023/11/01
-
Indian UGC (journal)
-
Refrences87
-
Citations1
-
Dekel Taliaz Taliaz Ltd., 2 Prof. Yehezkel Kaufmann Street, Textile Center (15th Floor), Tel Aviv 6801294, Israel ORCID
-
Alessandro Serretti Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy ORCID
Abstract
Cite
Taliaz, Dekel, and Alessandro Serretti. “Investigation of Psychoactive Medications: Challenges and a Practical and Scalable New Path”. CNS &Amp; Neurological Disorders - Drug Targets, vol. 22, no. 9, 2023, pp. 1267-74, https://doi.org/10.2174/1871527321666220628103843.
Taliaz, D., & Serretti, A. (2023). Investigation of Psychoactive Medications: Challenges and a Practical and
Scalable New Path. CNS &Amp; Neurological Disorders - Drug Targets, 22(9), 1267-1274. https://doi.org/10.2174/1871527321666220628103843
Taliaz D, Serretti A. Investigation of Psychoactive Medications: Challenges and a Practical and
Scalable New Path. CNS & Neurological Disorders - Drug Targets. 2023;22(9):1267-74.
Journal Categories
Medicine
Internal medicine
Neurosciences
Biological psychiatry
Neuropsychiatry
Medicine
Internal medicine
Neurosciences
Biological psychiatry
Neuropsychiatry
Neurology
Diseases of the nervous system
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Prevalence and drug use correlates of extra-medical use of prescription medications for sleep among adults in the United States: Results of the 2015–2018 National Survey on Drug Use and Health | Pharmacology Biochemistry and Behavior |
| 4 | 2021 |
| Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study | Progress in Neuro-Psychopharmacology and Biological Psychiatry |
| 19 | 2021 |
Optimizing prediction of response to antidepressant medications using machine learning and environmental data | European Psychiatry |
| 2 | 2021 |
| There are no patients without comorbidity | European Neuropsychopharmacology |
| 4 | 2021 |
Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing | Neuropsychopharmacology |
| 23 | 2021 |
Refrences Analysis
The category
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system: Psychiatry 56
is the most frequently represented among the references in this article. It primarily includes studies from Journal of Clinical Psychopharmacology The chart below illustrates the number of referenced publications per year.
